Issue 2

Oct 9, 2016

0

Issue 2

Posted in : Newsletter on by : biostemi trial

Dear BIOSTEMI Investigators and Study Teams,

 

We are pleased to introduce you to the second issue of the BIOSTEMI Study Newsletter.

To date, a total of 10 study sites have been initiated. 8 study sites have started the screening process and we have already randomized a total of 199 subjects.

During the last month, the first patient was randomized at the following study centers:

  • Zurich, Stadtspital Triemli, on 3 September 2016
  • Geneva, HUG, on 7 September 2016
  • Aarau, Kantonsspital, on 7 September 2016
  • Sion, Hôpital du Valais, on 8 September 2016
  • Fribourg, Hôpital Cantonal, on 9 September 2016
  • St Gallen, Kantonsspital, on 19 September 2016

We would like to congratulate Dr med. D.J. Kurz, Prof. med. M. Roffi, Dr med. A. Vuilliomenet, Dr med. M. Tapponnier, Prof. med. S. Cook, Dr med. D. Weilenmann and their study teams for the inclusion of the first patient at their study sites!

 

We encourage all remaining initiated study sites to start screening and we are looking forward to seeing the first patients randomized at these sites!

 

capture-decran-2016-10-09-a-11-25-15

STUDY CENTERS

At the moment, 10 study centers have been initiated and 8 study sites are actively enrolling patients in the BIOSTEMI study. Please see here below the current list of investigators and initiated study sites.

LIST OF STUDY CENTERS

 

 

STUDY STATUS

A total of 199 patients have been enrolled in the BIOSTEMI trial. 61 additional patients have been randomized during the last month. Please see here below the latest enrolment chart.

 

ENROLMENT CHART: OVERALL (updated 30.09.2016)

capture-decran-2016-10-09-a-11-26-01

 

ENROLMENT CHART ACCORDING TO STUDY SITE (updated 30.09.2016)

capture-decran-2016-10-09-a-11-26-11

ENROLMENT CHART: LAST MONTH (updated 30.09.2016)

capture-decran-2016-10-09-a-11-26-24

 

BIOSTEMI WEBSITE

We are pleased to inform you that the BIOSTEMI trial website has been recently launched. The official study webpage (www.biostemi-trial.ch) provides all information related to the BIOSTEMI trial, including a monthly updated enrolment status, official study documents and contact details.

 

We would like to thank you all very much for your efforts and commitment to the BIOSTEMI study. Please do not hesitate to contact us in case of questions or concerns related to the study.

 

 

Yours sincerely,

 

 

 

Dr. med. Juan F. Iglesias

Lausanne University Hospital

Switzerland

E-mail: juan-fernando.iglesias@chuv.ch

 

 

Prof. med. Thomas Pilgrim

Bern University Hospital

Switzerland

E-mail: Thomas.pilgrim.insel.ch

 

 

Dr. med. Olivier Muller

Lausanne University Hospital

Switzerland

E-mail: olivier.muller@chuv.ch